Global Infectious Vaccines Partnering Terms and Agreements 2014 to 2021: Deal trends, players and financials

Publisher Name :
Date: 01-May-2021
No. of pages: 400
Inquire Before Buying

The Global Infectious Vaccines Partnering Terms and Agreements 2014 to 2021: Deal trends, players and financials report provides a detailed understanding and analysis of how and why companies enter infectious vaccines partnering deals. The majority of deals are development stage whereby the licensee obtains a right or an option right to license the licensors vaccine technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. The report also includes adjuvant deals and alliances.

This report provides details of the latest infectious vaccines agreements announced in the healthcare sectors.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of all infectious vaccines partnering deals announced since January 2014, including financial terms where available, including over 650 links to online deal records of actual infectious vaccines partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of Infectious Vaccines dealmaking and business activities.

Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Infectious Vaccines dealmaking since 2014, including details of average headline, upfront, milestone and royalty terms. Infectious Vaccines deals since 2014. Deals are listed by headline value, signed by big pharma, most active Infectious Vaccines dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 3 provides a review of the leading Infectious Vaccines deals since 2014. Deals are listed by headline value, signed by big pharma, most active Infectious Vaccines dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in Infectious Vaccines dealmaking with a brief summary followed by a comprehensive listing of Infectious Vaccines deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides a comprehensive and detailed review of Infectious Vaccines partnering deals signed and announced since Jan 2014, where a contract document is available in the public domain. The chapter is organized by company A-Z, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive and detailed review of Infectious Vaccines partnering deals signed and announced since Jan 2014. The chapter is organized by specific Infectious Vaccines technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided organized by Infectious Vaccines partnering company A-Z, deal type definitions and Infectious Vaccines partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. The report also includes numerous tables and figures that illustrate the trends and activities in Infectious Vaccines partnering and dealmaking since Jan 2014.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Infectious Vaccines technologies and products.

Report scope

Global Infectious Vaccines Partnering Terms and Agreements 2014 to 2021: Deal trends, players and financials is intended to provide the reader with an in-depth understanding and access to infectious vaccines trends and structure of deals entered into by leading companies worldwide. Global Infectious Vaccines Partnering Terms and Agreements 2014 to 2021: Deal trends, players and financials includes:

Trends in infectious vaccines dealmaking in the biopharma industry since 2014

Analysis of infectious vaccines deal structure

Access to headline, upfront, milestone and royalty data

Access to over 650 infectious vaccines deal records

Identify the most active infectious vaccine dealmakers since 2014

The leading infectious vaccines deals by value since 2014

Includes adjuvant deals and alliances since 2014

In Global Infectious Vaccines Partnering Terms and Agreements 2014 to 2021: Deal trends, players and financials, the available deals are listed by:

Company A-Z

Headline value

Stage of development at signing

Deal component type

Specific infectious therapy target

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Global Infectious Vaccines Partnering Terms and Agreements 2014 to 2021: Deal trends, players and financials report provides comprehensive access to available deals and contract documents for over 650 infectious vaccines deals. Analyzing actual contract agreements allows assessment of the following:

What are the precise rights granted or optioned?

What is actually granted by the agreement to the partner company?

What exclusivity is granted?

What is the payment structure for the deal?

How are sales and payments audited?

What is the deal term?

How are the key terms of the agreement defined?

How are IPRs handled and owned?

Who is responsible for commercialization?

Who is responsible for development, supply, and manufacture?

How is confidentiality and publication managed?

How are disputes to be resolved?

Under what conditions can the deal be terminated?

What happens when there is a change of ownership?

What sublicensing and subcontracting provisions have been agreed?

Which boilerplate clauses does the company insist upon?

Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?

Which jurisdiction does the company insist upon for agreement law?

Global Infectious Vaccines Partnering Terms and Agreements provides the reader with the following key benefits:

In-depth understanding of infectious vaccines deal trends since 2014

Access infectious vaccines deal headline, upfront, milestone and royalty data

Comprehensive access to over 650 links to actual infectious vaccines deals entered into by the world's biopharma companies, together with real world clause examples

Identify leading infectious vaccines deals by value since 2014

Identify the most active infectious vaccines dealmakers since 2014

Insight into the terms included in infectious vaccines agreement, together with real world clause examples

Understand the key deal terms companies have agreed in previous deals

Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Global Infectious Vaccines Partnering Terms and Agreements 2014 to 2021: Deal trends, players and financials

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Infectious Vaccines dealmaking
2.1. Introduction
2.2. Infectious Vaccines partnering over the years
2.3. Most active Infectious Vaccines dealmakers
2.4. Infectious Vaccines partnering by deal type
2.5. Infectious Vaccines partnering by therapy area
2.6. Deal terms for Infectious Vaccines partnering
2.6.1 Infectious Vaccines partnering headline values
2.6.2 Infectious Vaccines deal upfront payments
2.6.3 Infectious Vaccines deal milestone payments
2.6.4 Infectious Vaccines royalty rates

Chapter 3 - Leading Infectious Vaccines deals
3.1. Introduction
3.2. Top Infectious Vaccines deals by value

Chapter 4 - Most active Infectious Vaccines dealmakers
4.1. Introduction
4.2. Most active Infectious Vaccines dealmakers
4.3. Most active Infectious Vaccines partnering company profiles


Chapter 5 - Infectious Vaccines contracts dealmaking directory
5.1. Introduction
5.2. Infectious Vaccines contracts dealmaking directory


Chapter 6 - Infectious Vaccines dealmaking by technology type


Chapter 7 - Partnering resource center
7.1. Online partnering
7.2. Partnering events
7.3. Further reading on dealmaking

Appendices

Appendix 1 - Infectious Vaccines deals by company A-Z

Appendix 2 - Infectious Vaccines deals by stage of development

Discovery
Preclinical
Phase I
Phase II
Phase III
Regulatory
Marketed
Formulation

Appendix 3 - Infectious Vaccines deals by deal type

Asset purchase
Assignment
Bigpharma outlicensing
Co-development
Collaborative R&D
Co-market
Co-promotion
CRADA
Development
Distribution
Equity purchase
Evaluation
Grant
Joint venture
Licensing
Manufacturing
Marketing
Option
Promotion
Research
Settlement
Spin out
Sub-license
Supply
Technology transfer
Termination

Appendix 4 - Infectious Vaccines deals by therapy area

Appendix 5 - Deal type definitions

About Wildwood Ventures
Current Partnering
Current Agreements
Recent report titles from Current Partnering


Table of figures

Figure 1: Infectious Vaccines partnering since 2014
Figure 2: Active Infectious Vaccines dealmaking activity since 2014
Figure 3: Infectious Vaccines partnering by deal type since 2014
Figure 4: Infectious Vaccines partnering by disease type since 2014
Figure 5: Infectious Vaccines deals with a headline value
Figure 6: Infectious Vaccines deals with an upfront value
Figure 7: Infectious Vaccines deals with a milestone value
Figure 8: Infectious Vaccines deals with a royalty rate value
Figure 9: Top Infectious Vaccines deals by value since 2014
Figure 10: Most active Infectious Vaccines dealmakers since 2014
Figure 11: Online partnering resources
Figure 12: Forthcoming partnering events
  • Global Cephalosporin Market Insights and Forecast to 2027
    Published: 06-May-2021        Price: US 4900 Onwards        Pages: 153
    Cephalosporin market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Cephalosporin market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2016-2027. Segment by Type - First Generation Cephalosporin - Second Generation Cephalosporin - Third Generation Cephalosporin ......
  • Global Miconazole Nitrate Sales Market Report 2021
    Published: 05-May-2021        Price: US 4000 Onwards        Pages: 123
    The global Miconazole Nitrate market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Miconazole Nitrate market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), by Type and by Application for the period 2016-2027. Segment by Type - Oral - Cream Segment by ......
  • Global Niclosamide Sales Market Report 2021
    Published: 05-May-2021        Price: US 4000 Onwards        Pages: 124
    The global Niclosamide market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Niclosamide market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), by Type and by Application for the period 2016-2027. Segment by Type - 95% Niclosamide - 96%-98% Niclosamide - 99% Ni......
  • Global Infectious Vaccines Partnering Terms and Agreements 2014 to 2021: Deal trends, players and financials
    Published: 01-May-2021        Price: US 3495 Onwards        Pages: 400
    The Global Infectious Vaccines Partnering Terms and Agreements 2014 to 2021: Deal trends, players and financials report provides a detailed understanding and analysis of how and why companies enter infectious vaccines partnering deals. The majority of deals are development stage whereby the licensee obtains a right or an option right to license the licensors vaccine technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. The report a......
  • Global Antibiotics Partnering Terms and Agreements 2010 to 2021
    Published: 01-May-2021        Price: US 3495 Onwards        Pages: 300
    The Global Antibiotics Partnering Terms and Agreements 2010 to 2021 report provides an understanding and access to the antibiotics partnering deals and agreements entered into by the worlds leading healthcare companies. Trends in antibiotics partnering deals Disclosed headlines, upfronts, milestones and royalties by stage of development Antibiotics partnering contract documents Top antibiotics deals by value The Global Antibiotics Partnering Ter......
  • Pneumocystisosis (Infectious Disease) - Drugs in Development, 2021
    Published: 30-Apr-2021        Price: US 2000 Onwards        Pages: 35
    Pneumocystisosis (Infectious Disease) - Drugs in Development, 2021 Summary Pneumocystisosis (Infectious Disease) - Drugs in Development, 2021 provides an overview of the Pneumocystisosis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Pneumocystisosis, complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report ......
  • Pseudomonas Aeruginosa Infections (Infectious Disease) - Drugs in Development, 2021
    Published: 30-Apr-2021        Price: US 2500 Onwards        Pages: 220
    Pseudomonas Aeruginosa Infections (Infectious Disease) - Drugs in Development, 2021 Summary Pseudomonas Aeruginosa Infections (Infectious Disease) - Drugs in Development, 2021 provides an overview of the Pseudomonas Aeruginosa Infections pipeline landscape. The report provides comprehensive information on the therapeutics under development for Pseudomonas Aeruginosa Infections, complete with analysis by Stage of Development, Drug Target, Mechanism of Action......
  • Pulmonary Tuberculosis (Infectious Disease) - Drugs in Development, 2021
    Published: 30-Apr-2021        Price: US 2000 Onwards        Pages: 50
    Pulmonary Tuberculosis (Infectious Disease) - Drugs in Development, 2021 Summary Pulmonary Tuberculosis (Infectious Disease) - Drugs in Development, 2021 provides an overview of the Pulmonary Tuberculosis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Pulmonary Tuberculosis, complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Mo......
  • Crimean-Congo Hemorrhagic Fever (Infectious Disease) - Drugs in Development, 2021
    Published: 30-Apr-2021        Price: US 2000 Onwards        Pages: 35
    Crimean-Congo Hemorrhagic Fever (Infectious Disease) - Drugs in Development, 2021 Summary Crimean-Congo Hemorrhagic Fever (Infectious Disease) - Drugs in Development, 2021 provides an overview of the Crimean-Congo Hemorrhagic Fever pipeline landscape. The report provides comprehensive information on the therapeutics under development for Crimean-Congo Hemorrhagic Fever, complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), ......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs